Ferucarbotran-enhanced magnetic resonance imaging versus gadoxetic acid-enhanced magnetic resonance imaging for the preoperative detection of hepatocellular carcinoma: Initial experience

Journal of Computer Assisted Tomography

Volumn 34, Issue 1, 2010, Pages 127-134

  Lee, Ji Young ^a   Kim, Seong Hyun ^b   Jeon, Yong Hwan ^c   Lee, Jongmee ^d   Kim, Min Ju ^d   Choi, Dongil ^b   Lee, Won Jae ^b  

^a School of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

^d Korea University Ansan Hospital   (South Korea)

Author keywords

Diagnosis; Ferucarbotran; Gadoxetic acid; Hepatocellular carcinoma; MRI

Indexed keywords

DIAGNOSIS; MAGNETISM; RESONANCE; TUMORS;

DIAGNOSTIC ACCURACY; DIAGNOSTIC PERFORMANCE; FERUCARBOTRAN; GADOXETIC ACID; HEPATOCELLULAR CARCINOMA; MEAN DIAMETER; MR-IMAGES; NEGATIVE PREDICTIVE VALUE; POSITIVE PREDICTIVE VALUES; RECEIVER OPERATING CHARACTERISTIC CURVES;

MAGNETIC RESONANCE IMAGING;

FERUCARBOTRAN; GADOXETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 76449088581     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/RCT.0b013e3181b1587a     Document Type: Article

References (34)

1. Larson RE, Semelka RC. Magnetic resonance imaging of the liver. Top Magn Reson Imaging. 1995;7:71-81.
2. Bartolozzi C, Lencioni R, Donati F, et al.. Abdominal MR: liver and pancreas. Eur Radiol. 1999;9:1496-1512.
3. Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology. 2001;218:27-38.
4. Saini S, Stark DD, Hahn PF, et al.. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology. 1987;162:211-216. (Pubitemid 17001812)
5. Kim YK, Kim CS, Lee YH, et al.. Comparison of superparamagnetic iron oxide-enhanced and gadobenate dimeglumine-enhanced dynamic MRI for detection of small hepatocellular carcinomas. AJR Am J Roentgenol. 2004;182:1217-1223.
6. Pauleit D, Textor J, Bachmann R, et al.. Hepatocellular carcinoma: detection with gadolinium- and ferumoxides-enhanced MR imaging of the liver. Radiology. 2002;222:73-80.
7. Tang Y, Yamashita Y, Arakawa A, et al.. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging. AJR Am J Roentgenol. 1999;172: 1547-1554.
8. Vogl TJ, Hammerstingl R, Schwarz W, et al.. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology. 1996;198: 881-887.
9. Kim SJ, Kim SH, Lee J, et al.. Ferucarbotran-enhanced 3.0-T magnetic resonance imaging using parallel imaging technique compared with triple-phase multidetector row computed tomography for the preoperative detection of hepatocellular carcinoma. J Comput Assist Tomogr. 2008;32:379-385.
10. Chang JM, Lee JM, Lee MW, et al.. Superparamagnetic iron oxide-enhanced liver magnetic resonance imaging: comparison of 1.5 T and 3.0 T imaging for detection of focal malignant liver lesions. Invest Radiol. 2006;41:168-174.
11. Huppertz A, Haraida S, Kraus A, et al.. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology. 2005;234:468-478.
12. Chakraborty DP, Winter LH. Free-response methodology: alternate analysis and a new observer-performance experiment. Radiology. 1990;174:873-881.
13. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839-843.
14. Bennett BM. On comparisons of sensitivity, specificity and predictive value of a number of diagnostic procedures. Biometrics. 1972;28: 793-800.
15. Fleiss JL. Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons, 1981.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236.
17. Willatt JM, Hussain HK, Adusumilli S, et al.. MR imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247:311-330.
18. Hwang HS, Kim SH, Jeon TY, et al.. Hypointense hepatic lesions depicted on gadobenate dimeglumine-enhanced three-hour delayed hepatobiliary-phase MR imaging: differentiation between benignancy and malignancy. Korean J Radiol. 2009;10:294-302.
19. Kim SH, Choi D, Kim SH, et al.. Ferucarbotran-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2005;184:1069-1076.
20. Bolondi L, Gaiani S, Celli N, et al.. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005;42:27-34.
21. Namkung S, Zech CJ, Helmberger T, et al.. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging. 2007;25: 755-765.
22. Hamm B, Staks T, Muhler A, et al.. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785-792.
23. Schuhmann-Giampieri G, Schmitt-Willich H, Press WR, et al.. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992;183:59-64.
24. Van Montfoort JE, Stieger B, Meijer DK, et al.. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1. J Pharmacol Exp Ther. 1999;290:153-157.
25. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, et al.. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med. 1991;22:233-237; discussion 242.
26. Reimer P, Rummeny EJ, Shamsi K, et al.. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996;199:177-183.
27. Huppertz A, Balzer T, Blakeborough A, et al.. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology. 2004;230:266-275.
28. Cheng WZ, Zeng MS, Yan FH, et al.. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol. 2007;13:4891-4896.
29. Kim YK, Kwak HS, Kim CS, et al.. Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT. Radiology. 2006;238:531-541.
30. Kurihara Y, Yakushiji YK, Tani I, et al.. Coil sensitivity encoding in MR imaging: advantages and disadvantages in clinical practice. AJR Am J Roentgenol. 2002;178:1087-1091.
31. Kim SH, Choi D, Lim HK, et al.. Detection of hepatic VX2 carcinomas with ferucarbotran-enhanced magnetic resonance imaging in rabbits: comparison of nine pulse sequences. Eur J Radiol. 2006;59:413-423.
32. Kim JI, Lee JM, Choi JY, et al.. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008; 43:202-210.
33. Kang BK, Lim JH, Kim SH, et al.. Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology. 2003;226:79-85.
34. Kim SH, Lee WJ, Lim HK, et al.. SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings. Korean J Radiol. 2009;10:112-120.